Oxurion NV
F:TG40
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value for Oxurion NV.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Oxurion Does
Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company employs 11 full-time employees The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013.
- Headquarters
- Belgium BE
- Employees
- 11
- IPO date
- Jul 7, 2006
Balance Sheet
Continue TG40 Research
Decided on Oxurion? Get an email when TG40 reaches the price you’d buy at. Free with an account.